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Context: Adiponectin may influence the risk of coronary heart dis-
ease (CHD) independently of traditional cardiovascular risk factors.
Objective: Because body composition and adiponectin levels vary by
race, we examined the relationship of adiponectin with prevalent and
incident CHD in a cohort of older Black and White adults.
Design andSetting:We conducted a cross-sectional and prospective
cohort study at two U.S. clinical centers.
Participants: Participants included 3075 well-functioning adults
between ages 70 and 79 yr enrolled in the Health, Aging, and Body
Composition study.
Main Outcome Measures: Prevalent CHD was defined as history
of myocardial infarction, coronary artery bypass graft, percutaneous
coronary transluminal angioplasty, angina, or major electrocardio-
gramabnormalities.After excluding thosewithprevalentCHD, incident
CHD was defined as hospitalized myocardial infarction or CHD death.
Results: At baseline, 602 participants (19.6%) had CHD. During
6 yr of follow-up, 262 (10.6%) incident CHD events occurred.Whites
had higher median adiponectin than Blacks (12 vs. 8 g/ml, P 
0.001). Race modified the effect of adiponectin (P for interaction
was 0.002 for prevalent CHD, and P  0.02 for incident CHD).
Among Whites, an inverse association of adiponectin with CHD
was explained by high-density lipoprotein and glucose. Among
Blacks, a doubling of adiponectin was associated with a 40% higher
risk of both prevalent CHD (odds ratio, 1.41; 95% confidence in-
terval, 1.11–1.78) and incident CHD (hazards ratio, 1.37; 95%
confidence interval, 1.01–1.87) after adjusting for explanatory
variables.
Conclusion: High circulating concentrations of adiponectin were
associated with higher risk of CHD in older Blacks, even accounting
for traditional CHD risk factors. (J Clin Endocrinol Metab 91:
5044–5050, 2006)
SEVERAL CYTOKINES AND cellular responses to inflam-mation have been implicated in the development of car-
diovascular disease. Adipose tissue secretes a number of hor-
mones, inflammatory proteins, and cytokines, collectively
termed as adipocytokines, potentially linking obesity to insulin
resistance and modulating the relationship between obesity
and an increased risk of coronary heart disease (CHD).
Circulating levels of adiponectin, unlike other proteins
secreted from adipose tissue, are lower in obese persons (1),
those with type 2 diabetes (2), and in coronary artery disease
(3, 4). Thus, adiponectin has been hypothesized to be an
antidiabetic, antiatherosclerotic, and antiinflammatory hor-
mone (5).
However, studies that have examined the relationship of
adiponectin with incident CHD have yielded inconsistent
results. A prospective study in White men reported a sig-
nificant inverse association between plasma adiponectin lev-
els and incident CHD (6, 7), whereas in a study of Native
Americans, adiponectin was not associated with CHD (8).
Ethnic differences in disease associations for adiponectin
may exist because of biological differences in the determi-
nants of and metabolic mechanisms by which adiponectin
acts. Specifically, levels of total adiposity, visceral fat area,
and lipid concentrations differ greatly between Blacks and
Whites (9), and levels of circulating adiponectin are signif-
icantly lower in Black Americans than in Whites (10, 11);
therefore, it is possible that adiponectin may differentially
predict disease in these two racial groups. No studies have
examined whether adiponectin is independently associated
with CHD similarly among Black Americans and Whites.
To investigate this question, we examined the association
between serum adiponectin among older White and Black
men and women enrolled in the Health, Aging, and Body
Composition (Health ABC) Study. We determined whether
adiponectin was associated with prevalent or incident CHD
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in the whole cohort and whether the relationship of adi-
ponectin with CHD was modified by sex, race, level of ad-
iposity, or other metabolic risk factors.
Subjects and Methods
Participants enrolled in the Health ABC study were well-functioning
men and women between the ages of 70 and 79 yr who were recruited
from April 1997 to June 1998 from a random sample of Medicare ben-
eficiaries residing in the areas surrounding Pittsburgh, PA, and Mem-
phis, TN. To be eligible for the study, participants had to report no
difficulty in walking one quarter mile, climbing 10 steps, or performing
basic activities of daily living. Individuals requiring assistive devices for
ambulation, subjects with difficulty performing activities of daily living
or life-threatening cancers, and those planning to leave the area within
3 yr were excluded from the study.
We first performed a cross-sectional study using the baseline data
gathered in 1997–1998. We then performed a prospective analysis for
incident CHD with a mean length of follow-up of 6.1  1.8 yr.
The study was approved by the institutional review boards of the
University of California, San Francisco, University of Pittsburgh, and
University of Tennessee. All of the study participants provided written
informed consent to participate in the study.
Racial group, age, and sex were assessed by self-report during the
initial interview. On self-administered questionnaires, participants re-
ported their average weekly alcohol consumption. Physical activity was
assessed using self-report of walking and exercise, assigning kilocalories
per week to activities (12). Participants reported smoking history as
never, former, or current smoker. Each participant had seated systolic
and diastolic blood pressures measured by a manual sphygmomanom-
eter. Hypertension was defined by self-report of a diagnosis and use of
an antihypertensive medication or if systolic blood pressure was at least
140mmHgor if diastolic bloodpressurewas at least 90mmHg.Diabetes
was defined by self-report of diabetes diagnosis or use of diabetes drug
or if fasting plasma glucose was at least 126 mg/dl or 2-h postchallenge
glucose was at least 200 mg/dl. An intermediate category of glucose
regulation comprising participants with impaired fasting glucose (100–
125 mg/dl) (13) and/or impaired glucose tolerance (2-h postchallenge
glucose between 140 and 200 mg/dl) (14) was created. Otherwise, the
subjects were considered to have normal glucose tolerance.
Weight was measured on a standard balance beam scale and height
by a stadiometer, and body mass index (BMI) was calculated. We mea-
sured visceral fat area by computed tomography scans using Somatom
Plus 4 (Siemens, Erlangen, Germany), Picker PQ 2000S (MarconiMedical
Systems, Cleveland,OH), or a 9800Advantage scanner (General Electric,
Milwaukee, WI) using standardized protocols. Visceral fat was mea-
sured at the L4–L5 level after participants were in the supine position.
Visceral fat was manually distinguished from sc fat using the internal
abdominal wall fascial plane, and fat area was calculated using inter-
active data language development software (RSI Systems, Boulder, CO).
Participants had venipuncture performed at the baseline visit after an
overnight fast. Serum samples were frozen at 70 C and stored at
McKesson BioServices, Rockville, MD. Fasting lipoprotein levels (Vitros
950 analyzer; Johnson & Johnson, New Brunswick, NJ), and fasting and
2-h postchallenge plasma glucose by automated glucose oxidase reac-
tion (YSI 2300 Glucose Analyzer; YSI, Yellow Springs, OH) were mea-
sured. Fasting serum insulin was measured by RIA (Pharmacia, Upp-
sala, Sweden) only among participants without known diabetes at the
baseline examination.
Adiponectin was assayed in 2002–2003 from serum specimens that
were frozen approximately 6–7 yr earlier. Total circulating levels of
adiponectin were measured in duplicate by RIA (Linco Research, St.
Charles, MO) with an intraassay coefficient of variation of 1.8–3.6%.
Plasma high-sensitivity C-reactive protein (CRP) concentration was
measured in duplicate by ELISA (Calbiochem, San Diego, CA) within 1
yr of specimen collection and was standardized according to the World
Health Organization First International Reference Standard with a sen-
sitivity of 0.08 g/ml.
Outcomes
Prevalent CHD was defined using self-reported health history of
prior coronary artery bypass surgery or percutaneous coronary trans-
luminal angioplasty (PTCA), or prior myocardial infarction (MI) or
angina and the use of an anti-anginal medication; hospitalizations for
PTCA, coronary artery bypass graft, MI, or angina reported by the
Centers forMedicare andMedicaid services between 1992 and 1998; and
outpatient visits with PTCA, MI, or angina diagnoses between 1995 and
1998. We also used definite electrocardiogram evidence of previous MI
with amajor Q-wave abnormality to classify participants with prevalent
CHD.
After excluding those with prevalent CHD, incident CHD was de-
fined as any overnight hospitalization forMI or coronary death. Incident
MI was determined by self-report at annual study assessment visits or
during 6-month interim telephone follow-up assessments. All MI diag-
noses were confirmed by review of hospital records for symptoms,
electrocardiogram changes, and cardiac enzyme or troponin elevations.
CHD death was defined as death from MI as the underlying cause,
sudden death in the setting of aCHDhistory, or absence of an alternative
cause based on review of medical records, death certificate, and an
informant interview (15). Additionally, all hospitalizations and all
deaths that occurred underwent a complete medical record review to
capture any other cases of nonfatal or fatal CHD.
Statistical analysis
In preliminary analyses, univariate associations of baseline covariates
with prevalent CHD were assessed using 2, t, and Wilcoxon tests as
appropriate; for incident CHD, unadjusted Cox models were used for
this step. We log transformed adiponectin, high-density lipoprotein
(HDL)-cholesterol, fasting insulin, and CRP to meet linearity assump-
tions and rescaled abdominal visceral fat and BMI by their sd to compare
associations with these predictors directly. We also assessed the corre-
lation between adiponectin and other fat andmetabolic variables overall
and by race and sex.
We used multivariable logistic regression to examine adjusted asso-
ciations between adiponectin and prevalent CHD and the Cox propor-
tional hazards model for incident CHD. We examined the effects of
adiponectin 1) after log transformation such that the resulting odds and
hazard ratios estimate the effect of a doubling of adiponectin and 2) by
quartiles. In nested sequences of models using log-transformed adi-
ponectin, we first adjusted for age, sex, and study site. Next, we added
all potential confounders, including current smoking, hypertension,
low-density lipoprotein (LDL)-cholesterol, BMI, abdominal visceral fat,
and medication use, thereby obtaining an estimate of the overall inde-
pendent effect of adiponectin. Finally, we added potential mediators of
the effects of adiponectin: glucose subgroup, HDL, CRP, and fasting
insulin, in separate steps. This explanatory analysis provides an estimate
of the direct effects of adiponectin via pathways other than through these
mediators.
We examined whether the association of adiponectin with CHD var-
ied by sex or race using themultivariatemodels adjusted for all potential
confounders, but not including the potential mediators. Because we
found striking evidence of an interaction by race,we repeated our nested
sequences of models separately by race.
To check these models, we examined whether the race-specific as-
sociations of adiponectin with prevalent CHD were similar by sex, BMI
categories, and visceral fat area. In the Cox models, the proportional
hazards assumption was verified by examining plots of Schoenfeld
residuals (16) vs. transformed time and by assessing interactions of all
predictors with time. We used SAS version 8.2 (SAS Institute, Cary, NC)
and SPlus version 6.1 (Insightful Corp., Seattle, WA) to perform the
analyses.
Results
At baseline, 602 participants (20%) had CHD. White men
had the highest prevalence of CHD (264 of 939, 28%) and
White women had the lowest (101 of 855, 12%), whereas
CHD prevalence for Black men was 22% (121 of 552) and for
Blackwomenwas 16% (116 of 729). Baselinemean values and
bivariate relationships with prevalent CHD are shown in
supplemental Table 1, published as supplemental data on
The Endocrine Society’s Journals Online web site at http://
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jcem.endojournals.org. After excluding all individuals with
prevalent CHD (n  237), over an average 6.1  1.8 yr of
follow-up, 262 participants (10.6%) developedCHD.Of these
events, only 32 (12%) were from CHD death. Overall, there
was a slightly higher incidence of CHD among Whites com-
pared with Blacks (18.7 vs. 15.2 per 1000 person-years, P 
0.11). Men had a higher incidence of CHD than women (23.1
vs. 12.8, P  0.001). White men had the highest incidence
(26.1) and White women the lowest (12.5). Incidence rates in
Black men and women were 18.3 and 13.2, respectively.
We examined the correlation between serum adiponectin
levels and several metabolic covariates. The correlations
were modest and similar between racial groups. Among
Whites, the Spearman correlation between adiponectin and
BMI was 0.30, for abdominal visceral fat was 0.43, for
HDL-cholesterol was 0.52, for CRP was 0.06, for fasting
glucose was 0.35, and for fasting insulin was 0.40. For
Black adults, the correlation between adiponectin and BMI
was 0.22, for abdominal visceral fat was 0.35, for HDL-
cholesterol was 0.45, for CRP was 0.13, for fasting glucose
was 0.29, and for fasting insulin was 0.32.
We examined the bivariate association between the co-
variates and incident CHD by racial group (Table 1). Several
metabolic variables such as BMI, abdominal visceral fat,
LDL, triglycerides, and fasting insulin were similar between
Blacks with and without incident CHD, whereas in Whites,
these variablesweremore abnormal among thosewith CHD.
Median values of total adiponectin did not differ between
Blacks with and without CHD, whereas adiponectin levels
were significantly lower amongWhiteswhodevelopedCHD
compared with Whites without CHD.
To determine the association between adiponectin and
prevalent and incident CHD, we constructed multivariable
logistic regression models adjusting for traditional cardiac
risk factors as well as all additional covariates and confound-
ers associated with CHD. We found that the association
between log adiponectin and prevalent and incident CHD
was significantly stronger in Blacks (P for interaction 0.002
for prevalent CHD, and P 0.02 for incident CHD), but was
similar in men and women. Therefore, we performed race-
specific models.
Figure 1 displays the association of log adiponectin with
prevalent CHD with sequential adjustment. In Whites, the
initially protective association of adiponectin with prevalent
CHD adjusting only for age, sex, and study site [odds ratio
(OR), 0.78; 95% confidence interval (CI), 0.68–0.91) was at-
tenuated after adjusting for traditional cardiac risk factors
and other confounders. This was further attenuated after
adjustment for variables potentially in the causal pathway
TABLE 1. Characteristics of the study population by race and incident CHD status
Blacks (n  1044) Whites (n  1429)
Incident CHD,
n  96
No CHD,
n  948
P Incident CHD,
n  166
No CHD,
n  1263
P
Age (yr) 73.3  3.0 73.3  2.8 0.83 73.8  3.0 73.7  2.8 0.55
Female sex 50 (52.1) 563 (59.4) 0.17 61 (36.8) 693 (54.9) 0.001
Study site
Memphis, TN 46 (8.8) 476 (91.2) 0.67 76 (10.1) 676 (89.9) 0.06
Pittsburgh, PA 50 (9.6) 472 (90.4) 90 (13.3) 587 (86.7)
Education, more than high
school graduate
24 (25.0) 249 (26.3) 0.86 87 (52.4) 679 (53.8) 0.79
Current smoking 18 (18.8) 149 (15.7) 0.41 10 (6.0) 85 (6.7) 0.73
Alcohol use, 1 drink/wk 30 (31.3) 363 (38.3) 0.16 103 (62.1) 723 (57.2) 0.26
Physical activity (kcal/wk)a 217 (964) 240 (822) 0.88 708 (1802) 611 (1307) 0.38
Hypertensionb 72 (75.0) 668 (70.5) 0.35 105 (63.3) 650 (51.5) 0.004
Glycemic statusb
Diabetes 37 (38.5) 244 (25.7) 0.04 47 (28.3) 196 (15.5) 0.001
Intermediate glucose regulation 19 (19.8) 259 (27.3) 46 (27.7) 384 (30.4)
Normal glucose tolerance 39 (40.6) 391 (41.2) 73 (44.0) 644 (51.0)
BMI (kg/m2) 29.0  5.1 28.6  5.5 0.48 27.5  4.0 26.3  4.1 0.001
Abdominal visceral fat area (cm2) 141.2  71.1 127.6  60.8 0.08 163.0  78.1 145.6  66.4 0.007
LDL-cholesterol (mg/dl) 123.1  34.2 124.8  35.8 0.67 128.7  33.7 120.6  32.9 0.003
HDL-cholesterol (mg/dl)a 49.0 (15.0) 55.0 (21.0) 0.001 46.0 (17.5) 52.0 (21.0) 0.001
Triglycerides (mg/dl)a 110.0 (70.0) 104.0 (53.0) 0.25 137.0 (94.0) 128.0 (80.0) 0.04
Fasting insulin (IU/ml)a 7.9 (6.7) 7.5 (5.6) 0.56 7.4 (5.5) 6.2 (4.6) 0.006
CRP (mg/liter)a 2.4 (2.4) 2.0 (2.7) 0.41 1.7 (2.1) 1.5 (1.7) 0.20
Adiponectin (g/ml)a 8.0 (7.0) 8.0 (7.0) 0.75 10.0 (8.0) 12.0 (9.0) 0.001
Medication use
Aspirin 30 (31.3) 243 (25.6) 0.22 73 (44.0) 421 (33.3) 0.007
Statin 13 (13.5) 70 (7.4) 0.03 14 (8.4) 139 (11.0) 0.31
ACE inhibitor 22 (22.9) 144 (15.2) 0.05 22 (13.3) 139 (11.0) 0.39
Oral estrogen 6 (6.3) 68 (7.2) 0.74 17 (10.3) 228 (18.1) 0.01
The data exclude the 602 participants with prevalent CHD. All values represent n (%) or mean  SD. P values were by  2 or t test where
appropriate. ACE, angiotensin converting enzyme.
a Median (interquartile range) is reported for skewed variables, and P values are by Wilcoxon test.
b Hypertension defined as self-report of diagnosis and use of antihypertensive medication, or systolic blood pressure at least 140 mm Hg or
diastolic blood pressure at least 90 mm Hg. Diabetes is defined by self-report of diabetes diagnosis, use of diabetes drug, fasting glucose of at
least 126 mg/dl or 2-h postchallenge glucose of at least 200 mg/dl. Intermediate glucose regulation is defined if fasting glucose is 100–125 mg/dl
or if 2-h glucose is between 140–200 mg/dl. Normal glucose regulation is classified otherwise.
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including glucose, HDL-cholesterol, CRP, and fasting insulin
(OR, 1.08; 95% CI, 0.87–1.34) (Table 2).
Among Blacks, log adiponectin was not significantly as-
sociated with prevalent CHD in the model adjusting only for
age, sex, and study site (OR, 1.09; 95% CI, 0.92–1.29). How-
ever, after adjustment for traditional cardiac risk factors and
other covariates, higher adiponectin was associated with
prevalent CHD. After adjustment for the four variables po-
tentially in the causal pathway between adiponectin and
CHD, we found that a doubling of adiponectin was directly
associated with a 40% increased odds of CHD in Blacks (OR,
1.41; 95% CI, 1.01–1.78) (Table 2).
In multivariate Cox models for incident CHD, we found a
similar pattern of results for both Whites and Blacks as with
the prevalent CHD outcome (Fig. 2). In Whites, the initially
protective association between adiponectin and incident
CHD was attenuated to a lesser degree than in the prevalent
CHD models, with a hazards ratio (HR) of 0.85 (95% CI,
0.66–1.09) in the fully adjusted model. Among Blacks, a
doubling of adiponectin was independently associated with
an increased risk of incident CHD (HR, 1.37; 95% CI, 1.01–
1.87) after adjusting for confounders andmediators (Table 2).
In Fig. 3, the fully adjusted odds of CHD for each quartile
of adiponectin are shown separately by race. Because the
distribution of adiponectin differed significantly by race, we
used race-specific quartiles for these analyses. Among
Whites, risk of both prevalent and incident CHDwas similar
across quartiles of adiponectin. In contrast, among Blacks,
the odds of prevalent CHDwere significantly elevated in the
fourth quartile of adiponectin (12 g/ml) compared with
the first (OR, 2.53; 95% CI, 1.34–4.79); similarly, in the Cox
model for incident CHD, we found a trend toward increased
risk in the fourth quartile compared with the first (HR, 2.13;
95% CI, 0.91–4.95).
Finally, we examinedwhether the association of adiponec-
tin with prevalent CHD differed by sex, BMI category, or
abdominal visceral fat tertile separately by race. Because
abdominal visceral fatwas distributed differently by race,we
used race-specific tertiles. The adverse association with
higher adiponectin levels was observed only among Blacks
TABLE 2. Race-specific multivariate models for prevalent and incident CHD
Prevalent CHD OR (95% CI) Incident CHD HR (95% CI)
Blacks Whites Blacks Whites
Log adiponectin 1.41 (1.11–1.78) 1.08 (0.88–1.34) 1.37 (1.01–1.87) 0.85 (0.66–1.09)
Age, per yr 1.10 (1.03–1.17) 1.03 (0.98–1.08) 0.99 (0.91–1.07) 1.03 (0.98–1.10)
Sex, female vs. male 0.62 (0.41–0.93) 0.44 (0.31–0.64) 0.73 (0.43–1.24) 0.56 (0.38–0.83)
Study site, Memphis vs. Pittsburgh 0.73 (0.51–1.04) 1.05 (0.78–1.41) 1.16 (0.72–1.86) 1.14 (0.80–1.61)
Current smoking 0.54 (0.31–0.94) 0.79 (0.41–1.50) 1.29 (0.70–2.35) 1.17 (0.61–2.25)
Hypertension 1.49 (0.95–2.33) 1.68 (1.23–2.28) 1.20 (0.70–2.04) 1.48 (1.05–2.09)
LDL, per mg/dl 1.00 (0.99–1.01) 1.00 (0.99–1.00) 1.00 (0.99–1.01) 1.01 (1.00–1.01)
BMI, per SD kg/m2 0.88 (0.70–1.11) 0.92 (0.73–1.17) 0.83 (0.61–1.12) 1.15 (0.89–1.50)
Abdominal visceral fat, per SD cm2 1.14 (0.89–1.47) 0.96 (0.79–1.16) 1.19 (0.86–1.64) 0.84 (0.66–1.06)
Aspirin use 2.85 (1.99–4.07) 4.11 (3.07–5.49) 1.09 (0.65–1.82) 1.56 (1.12–2.18)
Statin use 3.42 (2.09–5.60) 3.20 (2.24–4.58)
Oral estrogen use 0.66 (0.30–1.47) 0.56 (0.31–1.01)
ACE inhibitor use 1.13 (0.72–1.78) 1.62 (1.11–2.37)
Potential explanatory variables
Glycemia categories (reference, normal glucose)
Intermediate glucose regulation 0.91 (0.59–1.39) 1.02 (0.73–1.42)
Diabetes 1.80 (1.15–2.83) 1.48 (0.99–2.20) 1.26 (0.70–2.25) 1.35 (0.88–2.05)
Log HDL 0.79 (0.38–1.62) 0.33 (0.18–0.61) 0.46 (0.18–1.17) 0.84 (0.41–1.74)
Log CRP 1.30 (1.06–1.60) 1.24 (1.04–1.48) 1.06 (0.80–1.40) 1.24 (1.00–1.53)
Log insulin 1.02 (0.71–1.47) 1.20 (0.89–1.63) 1.32 (0.84–2.06) 1.39 (0.96–1.99)
The incident CHD models are not adjusted for statin, oral estrogen, or angiotensin converting enzyme (ACE) inhibitor use because these
variables were not associated with the outcome; the diabetes variable is dichotomous for the incident CHD model.
FIG. 1. Association between adiponectin and prevalent
CHD with sequential adjustment by race. Model 1 is ad-
justed for age, sex, and study site. Model 2 is model 1 plus
current smoking, hypertension, LDL, aspirin use, BMI, ab-
dominal visceral fat, statin, oral estrogen, and angiotensin
converting enzyme inhibitor use. Model 2 is then adjusted
by glucose category, HDL-cholesterol, CRP, and fasting in-
sulin.
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who were normal weight or overweight but not for those
who were obese (OR, 1.58, 1.09–2.29 for BMI  25 kg/m2;
OR, 1.99, 1.36–2.91 for BMI 25–29.9 kg/m2; and OR, 0.83,
0.56–1.22 for BMI  30 kg/m2, P for interaction  0.002).
Discussion
Older White Americans had higher median serum levels
of total adiponectin compared with older Blacks. Adiponec-
tin was inversely associated with prevalent and incident
CHD in White men and women, but this relationship was
completely attenuated after adjustment for variables that
potentially underlie the influence of adiponectin on CHD
risk (HDL, inflammation/CRP, and glucose tolerance/insu-
lin sensitivity). Paradoxically, among Black subjects, adi-
ponectin was associated with a higher prevalence and inci-
dence of CHD, such that a doubling of adiponectin was
associated with an approximate 40% higher risk of CHD
independently of known biological pathways. This associa-
tionwasmost apparent in the highest quartile of adiponectin
(12 g/ml) and among normal or overweight Black
participants.
Adiponectin is a protein produced exclusively by adipo-
cytes and is homologous to collagen VIII and X and com-
plement factor C1q. Adiponectin circulates in a homotrimer
form, a low-molecular-weight hexamer, and high-molecular-
weight forms larger than 400 kDa (5), together accounting for
0.01% of total plasma protein (1). Commercially available
assays, including the one used in the present study, measure
total levels of circulating adiponectin. However, the ratio of
the high-molecular-weight form/total circulating adiponec-
tin (SA) has been best correlated with improvements in in-
sulin sensitivity and may therefore be the more sensitive
indicator of the protective effect of this protein (17). Our
finding of differential effects of adiponectin on CHD by race
raises the possibility that Blacks and Whites may differ with
respect to the proportions of the high-molecular-weight adi-
ponectin relative to total adiponectin levels.
Data from animal and in vitro studies suggest several
mechanisms by which adiponectin may affect atherosclero-
sis. In vitro studies show that adiponectin inhibits vascular
adhesion factors in endothelial cells (18), inhibits foam cell
formation (19), inhibits smooth muscle proliferation and mi-
gration (20), and suppresses growth and function of macro-
phages (19, 21). Animal studies have shown thatmice lacking
adiponectin have increased neointimal formation in re-
sponse to vascular cuff injury (20, 22), and overexpression of
the globular portion of adiponectin in a proatherogenic
mouse model decreased the development of atherosclerosis
(23).
Translating these laboratory findings to humans, early
clinical studies also found inverse associations between adi-
ponectin and CHD prevalence in Japanese men (18, 24, 25)
FIG. 2. Association between adiponectin and incident CHD
with sequential adjustment by race. Model 1 is adjusted for
age, sex, and study site. Model 2 is model 1 plus current
smoking, hypertension, LDL, aspirin use, BMI, and abdom-
inal visceral fat. Then, Model 2 is adjusted by glucose cat-
egory, HDL, CRP, and fasting insulin in separate stages.
FIG. 3. Fully adjusted association of each adiponectin
quartile and prevalent or incident CHD according to race.
Adiponectin quartile ranges are as follows: Whites, Q1  8
g/ml, Q2  8–11.9 g/ml, Q3  12–15.9 g/ml, Q4 
16 g/ml; Blacks, Q1  5 g/ml, Q2  5–7.9 g/ml, Q3 
8–11.9 g/ml, and Q4  12 g/ml. The prevalent CHD
model is adjusted for age, sex, study site, current smoking,
hypertension, LDL-cholesterol, aspirin use, statin, oral es-
trogen, angiotensin converting enzyme inhibitor use, BMI,
abdominal visceral fat area, glucose categories (normal, in-
termediate, and diabetes), HDL-cholesterol, CRP, and fast-
ing insulin. The incident CHD model is adjusted for age,
sex, study site, current smoking, hypertension, LDL-
cholesterol, aspirin use, BMI, abdominal visceral fat, dia-
betes, HDL, CRP, and fasting insulin.
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and hemodialysis patients in Italy (26). The largest published
study to datewas a nested case control study from theHealth
Professionals Follow-up Study in which 266 primarilyWhite
men developed CHD after 6 yr of follow-up (6). Adiponectin
remained inversely associated with CHD even after adjust-
ing for potential mediators including HDL, CRP, and gly-
cemia (relative risk, 0.56; 95%CI, 0.32–0.99) (6). Diabetic men
in this cohort also had an inverse association of adiponectin
with CHD, which was significantly attenuated by HDL-
cholesterol (7). However, more recent studies show incon-
sistent results. In a nested case control from the Strong Heart
Study, adiponectin was not associated with incident CHD
among Native Americans, irrespective of diabetes status (8).
In a nested case-control study of British women, adiponectin
was not associated with incident CHD (27). In a cross-
sectional study of young adults, adiponectin was positively
related to coronary artery calcium score after adjustment for
waist circumference and insulin (28). In the Dutch Hoorn
Study, adiponectin was inversely associated with nonfatal
cardiovascular disease but associated with an increased risk
of all-cause mortality (29). Lastly, in a Danish study, higher
levels of adiponectin were associated with increased risk of
total mortality among patients with congestive heart failure
(30). Our findings support the majority of previous findings
of a protective association of adiponectin with CHD among
White subjects but indicate that high adiponectin may be a
potentially harmful independent risk factor for CHD among
Blacks.
We found that Black adults have higher levels of HDL-
cholesterol and lower levels of triglycerides and abdominal
visceral fat than Whites. Racial differences in lipoprotein
distribution and body composition are well described (9, 31).
Low levels of lipoprotein lipase, a key enzyme involved in
lipid metabolism, are associated with a dyslipidemic profile:
low HDL and high triglycerides (32). Differences in lipopro-
tein levels by race are associated with lipase activity and
genetic variations in lipoprotein and hepatic lipase genes
(33). Blacks had higher lipoprotein lipase activity and re-
duced hepatic lipase activity compared with Whites in a
recent study, suggesting that this increased lipolytic activity
in Blacks may contribute to the favorable plasma lipoprotein
profile and lower levels of visceral fat (9). Lipoprotein lipase
activitywas shown to be positively correlatedwith adiponec-
tin levels independent of CRP and a measure of insulin
sensitivity (34). Although unknown, we suspect that the
high-molecular-weight formof adiponectin ismost related to
lipase activity. This line of evidence along with our hypoth-
esis that Blacks may have lower proportions of the high-
molecular-weight adiponectin relative to the total circulating
adiponectin concentrations raises the possibility that as adi-
ponectin levels increase in Blacks, and relative proportions of
high-molecular-weight adiponectin decrease, there may be a
down-regulation of lipoprotein lipase activity leading to a
less favorable lipoprotein profile and therefore increased risk
of CHD in Blacks.
We found no significant difference in total serum adi-
ponectin levels in Blacks with and without incident or prev-
alent CHD. However, with sequential adjustment of vari-
ables in our multivariate models, we observed an increased
risk emerge, giving evidence of negative confounding. With-
out taking these additional metabolic variables into account,
wewould underestimate the effect of adiponectinwith CHD.
The fully adjusted serum adiponectin levels for Blacks with
incident CHD was 9.22  1.06 g/ml vs. 8.05  1.02 g/ml
for Blacks without incident CHD, which is significantly
different.
A strength of this study resides in the measurements of
several metabolic factors as well as computed tomography
radiographic measures of body composition. However, be-
cause Health ABC is a cohort of community-dwelling older
adults without advanced physical or cognitive impairment,
it is possible that our findings reflect a healthy survivor
population that may not generalize to younger adults or
more frail elders. Although we followed a large number of
participants for several years, we may have had limited
power to examine associations with incident CHD in each
racial subgroup. Although we may have missed an inde-
pendent protective effect of adiponectin in Whites, we did
find statistical evidence of increased risk of higher adiponec-
tin levels in Blacks.
Even though we have adjusted our incident CHD models
for 13 additional variables, we cannot exclude the possibility
of residual confounding. Residual confounding could result
from using an imperfect surrogate for the true confounder,
e.g. using fasting insulin and glucose rather than a more
precise measure of insulin resistance. Additionally, we may
have failed to adjust for other potential confounders. More-
over, the association between adiponectin andCHD inBlacks
is of borderline significance and is estimated in a series of
models that may inflate the type I error. This is a limitation,
and this finding warrants confirmation in future studies of
African-American adults.
In conclusion, we found that high serum adiponectin lev-
els were associated with a lower risk of CHD among White
men andwomen,whichwas attenuated by glucose tolerance,
HDL-cholesterol, fasting insulin concentrations, and CRP.
However, in Black American men and women, adiponectin
was associated with increased risk for CHD after accounting
for other known modulators of CHD risk. If this finding is
confirmed in future studies, it raises the possibility of dif-
ferent mechanisms by which adiponectin may affect CHD
risk that is independent of lipoprotein or glucose
metabolism.
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